Source - RNS
RNS Number : 6259M
GlaxoSmithKline PLC
14 October 2016
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Andrew Witty

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.  

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£17.038876

6771

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

  

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.  

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£17.038876

86

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Lady C Witty

b)

Position/status

PCA of Sir Andrew Witty (Chief Executive Officer)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.  

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£17.038876

1897

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr J P Witty

b)

Position/status

PCA of Sir Andrew Witty (Chief Executive Officer)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

Acquisition of ordinary shares following the re-investment of dividends paid to shareholders on 13 October 2016.  

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£17.038876

55

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Witty

b)

Position/status

PCA of Sir Andrew Witty (Chief Executive Officer)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

  

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.  

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£17.038876

56

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I W Whyte

b)

Position/status

PCA of Mrs V A Whyte (Company Secretary)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.  

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£17.038876

371

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs D Connor

b)

Position/status

PCA of Mr R G Connor (President, Global Manufacturing & Supply)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016.  

 

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

£17.038876

217

 

 

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHQZLFFQBFBFBV

Related Charts

GlaxoSmithKline (GSK)

+5.25p (+0.36%)
delayed 08:24AM